Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. The company operates through three approved commercial products and an advancing pipeline leveraging its proprietary formulation technologies.

Xeris's commercial portfolio includes Recorlev, a cortisol synthesis inhibitor approved in 2022 for treating endogenous hypercortisolemia in adults with Cushing's syndrome, with potential to generate approximately one billion dollars in annual net revenue at peak penetration. Gvoke is a ready-to-use, room-temperature stable liquid glucagon product available in three presentations—HypoPen auto-injector, pre-filled syringe, and kit format—for treating severe hypoglycemia in pediatric and adult patients with diabetes. Keveyis is the first FDA-approved therapy for Primary Periodic Paralysis, an ultra-rare genetic neuromuscular disorder affecting approximately four thousand to five thousand people in the United States.

The company's lead pipeline program, XP-8121, represents a novel once-weekly subcutaneous injection of levothyroxine formulated with the company's proprietary XeriSol technology for treating hypothyroidism, with Phase 3 initiation planned for 2026. The estimated total addressable market for this therapy represents three to five million patients or more in the United States, representing a one to three billion dollar peak net sales opportunity.

Xeris's competitive advantages center on its proprietary non-aqueous formulation technologies, XeriSol and XeriJect, which enable ready-to-use, room-temperature stable, highly concentrated injectable formulations of both small and large molecules. These platforms eliminate the need for reconstitution and refrigeration while reducing injection volumes and enabling convenient subcutaneous or intramuscular administration. The company pursues formulation and development partnerships to apply these technologies to other companies' proprietary drugs and biologics across small molecules, peptides, biologics, and monoclonal antibodies.

Xeris contracts with third-party contract manufacturing organizations for production, assembly, testing, packaging, storage, and distribution of its products. The company maintains supply agreements with specialized manufacturers including Regis Technologies for levoketoconazole API, Lonza for Recorlev drug product, Bachem for glucagon API, Pyramid for Gvoke drug product, and SHL Medical for auto-injector components. Additional information is available at www.xerisbiopharma.com.